Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Spectrum Pharmaceuticals (NASDAQ:SPPI) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Spectrum and see what CAPS investors are saying about the stock right now.

Spectrum facts

Headquarters (founded)

Henderson, Nev. (1987)

Market Cap

$693.1 million



Trailing-12-Month Revenue

$250.6 million


Chairman/CEO Dr. Rajesh Shrotriya (since 2002)
Acting CFO Brett Scott (since 2010)

Return on Equity (average, past 3 years)


Cash / Debt

$146.6 million / $75.0 million


Biogen Idec
Teva Pharmaceutical

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 98% of the 454 members who have rated Spectrum believe the stock will outperform the S&P 500 going forward.

Just yesterday, one of those Fools, Googlespooch, succinctly summed up the Spectrum bull case for our community

The company has a strong pipeline of drugs, keeps getting approvals from the FDA, and has been building strong networks with physicians (prevents generics from taking back that much market share). Also, it has been said that Spectrum has only tapped roughly 50% of the possible physicians to date.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.